Overview
CJC 1295 is a growth hormone releasing hormone analog designed to support endogenous growth hormone secretion over an extended duration. Unlike shorter acting GHRH peptides, its longer activity profile allows for more sustained signaling across the growth hormone axis.
It is typically positioned within protocols focused on GH and IGF-1 support, recovery signaling, and body composition optimization while preserving endogenous pathway activation rather than replacing growth hormone directly. CJC 1295 is also frequently utilized alongside growth hormone secretagogues such as Ipamorelin, allowing for complementary signaling across both GHRH and ghrelin receptor pathways within structured GH axis protocols.
Mechanism of Action
CJC 1295 binds to growth hormone releasing hormone receptors in the anterior pituitary, stimulating endogenous growth hormone release. This supports downstream IGF-1 production and broader GH axis activity related to recovery, metabolism, and tissue maintenance.
Its extended half-life differentiates it from shorter acting peptides by providing more sustained stimulation of endogenous signaling pathways.
In combined protocols, pairing with ghrelin receptor agonists such as Ipamorelin allows for dual pathway stimulation, integrating GHRH mediated pituitary signaling with ghrelin driven GH release to support a more complete endogenous growth hormone response.
Clinical Applications
- Endogenous growth hormone support
- IGF-1 pathway signaling
- Recovery and tissue maintenance support
- Body composition optimization
- Structured GH axis protocols
- Combined GH axis protocols utilizing both GHRH and ghrelin pathway stimulation
Protocol Considerations
CJC 1295 is typically administered subcutaneously, with protocol frequency influenced by the specific form used and overall clinical goals. Its longer acting profile is often considered in programs seeking more sustained GH axis support rather than short pulse only signaling.
Use is generally evaluated within the context of endocrine status, recovery goals, and broader protocol design.
Platform Insight
Available Inside the Platform
Access deeper clinical protocols, dosing frameworks, patient response optimization strategies, and implementation guides inside the GC Scientific platform.
Access PlatformClinical Questions
CJC 1295 is a long-acting GHRH analogue that binds to growth hormone releasing hormone receptors in the anterior pituitary, stimulating endogenous GH secretion. Its extended half-life supports more sustained GH axis signaling compared to shorter acting GHRH peptides.
Sermorelin is generally shorter acting and more directly associated with endogenous pulse signaling, while CJC 1295 is designed for more sustained GH axis engagement. The choice is typically guided by whether short pulse stimulation or extended continuous signaling is the clinical objective.
Changes are generally gradual and depend on endocrine status, consistency of administration, and the broader physiologic context of the protocol. Early endocrine signaling shifts may occur within weeks, with more evaluable body composition and recovery changes typically emerging over 8 to 12 weeks.
While it can be used independently, it is often paired with ghrelin receptor agonists such as Ipamorelin to support complementary growth hormone signaling pathways within the GH axis.